Compulsory licence for another cancer drug?

Amiti Sen New Delhi | Updated on April 03, 2014 Published on April 02, 2014

DIPP wants to know why generic version of Bristol-Myers Squibb’s drug is needed

After allowing an Indian firm to sell the generic, or copied, version of Bayer’s anti-cancer drug Nexaver, the Centre is now considering doing the same for Dasatinib, made by US drug major Bristol-Myers Squibb (BMS) and sold under the brand name Sprycel.

Only, the Department of Industrial Policy and Promotion (DIPP) wants the Health Ministry to clarify the reason under which it wants approval.

If the Health Ministry can prove that denial of generic manufacture of this drug could lead to a national emergency or a situation of extreme urgency, the DIPP can allow its manufacture via a notification.

But if the Health Ministry wants the compulsory licence on the grounds that the patented version of the leukaemia drug is not affordable by the masses, then the approval of the Indian Patent Office is required. A month’s dosage of BMS’s patented medicine costs around ₹60,000.

Only one licence so far

India has granted only one compulsory licence — a permit to produce versions of patented medicines without the consent of the patent holder — so far. It has allowed Hyderabad-based Natco to sell a generic version of Bayer’s anti-cancer drug, Nexaver.

The Nexaver licence was, however, granted by the Indian Patent Office, not the DIPP, as it was sought on the grounds of non-availability and high price of the patented drug.

Approaching the Indian Patent Office for a compulsory licence under the Patents Act (Section 84) is more complicated than getting it under the provision (Section 92 of the Act) where the Centre issues a notification. Generic manufacturers have to go to the Patent Office individually to seek a licence. In October 2013, the Patent Office had rejected the application of Mumbai-based BDR Pharmaceuticals to make a generic version of Dasatinib.

Following this, the Health Ministry approached the DIPP, asking it to grant a licence by issuing a notification. “We pointed out to the Health Ministry that as per the law, we can do so only when it can conclusively prove that denying it could lead to a public health crisis, or if it gives an undertaking that it wants it for public non-commercial use, where the medicines will be purchased by the Government,” a DIPP official told Business Line.

The Health Ministry has to collate data on the number of patients suffering due to unavailability of the patented medicine to convince the Government that there are grounds to grant the compulsory licence to address a situation of public urgency or national emergency.

In case the Health Ministry wants the licence to be issued in order to bring down the price of the medicine and expand its reach, it has to be granted by the Controller of Patents, he added.

Published on April 02, 2014

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.